1. Speroff, L, Glass RH, Kase NG, eds. 1999 Clinical gynecologic endocrinology and infertility. 6th ed. pp. 654 - 707. Lippincott Williams and Wilkins, Baltimore, MD
2. Adashi EY, Rock JA, Rosenwaks Z, eds. 1996 Reproductive endocrinology, surgery, and technology. vol.2, p.1394. Lippincott - Raven, Philadelphia, PA.
3. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat Rep 50(15):1-108.
4. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. 1998 New Engl J Med Jul 2;339(1):12-20.
5. Judd HL, Mebane-Sims I, Legault C, Wasilaskas C, Johnson S, Merino M et al. 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199-208.
6. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. 1998 JAMA 279(18):1445-51.
7. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. 1990 Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 70(4):1132-5.
8. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. 1985 Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7:178-208.
9. Ettinger B. 1988 Prevention of osteoporosis: treatment of estradiol deficiency. Obstet Gynecol 72(5 supplem): 12S-17S.
10. Shoback D, Marcus R, Bikle D, Strewler G. Greenspan FS and Gardner DG, eds. Mineral metabolism and bone disease. Basic & clinical endocrinology, 6th ed. pp. 310-8.
11. The National Osteoporosis Foundation, http://www.nof.org/physguide/diagnosis.htm
12. Puntila E, Kroger H, Lakka T, Tuppurainen M, Jurvelin J, Honkanen R. 2001 Leisure-time physical activity and rate of bone loss among peri- and postmenopausal women: a longitudinal study. Bone 29(5): 442-6.
13. Dempster DW, Kurland ES, Zhou H, Nieves J, Woelfert L et al. 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16(10): 1846-53.
14. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J et al. 2000 Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 283(10): 1318-21.
15. Freedman RR. 1998 Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 70(2): 332-7.
16. Kimura D. 1995 Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav 29:312-21.
17. Shaywitz SE, Shaywitz BA, Pugh KR, Fulbright RK, Skudlarski P, Menck WE et al. 1999 Effects of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 281(13):1197-1202.
18. Barrett-Connor E, Kritz-Silverstein D. 1993 Estrogen replacement therapy and cognitive function in older women. JAMA 269:2637-41.
19. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al. 1997 A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study. Neurology 48(2):1517-21.
20. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B et al. 1996 Effects of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 348: 429-32.
21. Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M et al. 2000 Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54(7):833-7.
22. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA et al. 2001 High-dose estradiol improves cognition for women with AD: results of a randomized trial. Neurology 57(4):605-12.
23. Henderson VM, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51(9):896-900.
24. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al. 2000 Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 283(8): 1007-1015.
25. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D et al. 2000 Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 54: 295-301.
26. McEwen BS, Alves SE, Bulloch K, Weiland NG. 1997 Ovarian steroids and the brain: implications for cognition and aging. Neurology 48(Supplem 7): S8-15.
27. Gandy S, Duff K. 2000 Post-menopausal estrogen deprivation and Alzheimer's disease. Exp Gerontol 35(4):503-11.
27a. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. 2002 Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil and Steril 79(6): 1341-52.
28. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. 2000 Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New Engl J Med 343 (10): 682-8.
29. Arlt WA, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M et al. 1999 Dehydroepiandrosterone replacement in women with adrenal insufficiency. New Engl J Med 341 (14): 1013-20.
30. Sakorafas GH, Krespis E, Pavlakis G. 2002 Risk estimation for breast cancer development; a clinical perspective. Surg Oncol 10(4):183-192.
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288(3): 321-333.
32. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O et al. 1999 Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 130: 262-9.
33. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. 1995 Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85(1):11-7.
34. Delgado RC, Lubian Lopez DM. 2001 Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38(2):147-56.
35. Fisher B, Costantino JP, Wickerham DL, Redmond CK , Kavanah M, Cronin WM et al. 1998 Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371-88.
36. Powles TP, Eeles R, Ashley S, Easton D, Chang J, Dowsett et al. 1998 Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101.
37. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N et al. 1998 Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352:93-97.
38. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. 1999 Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282(7): 637-645.
39. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 2189-2197.
40. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K et al. 2002 Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 287(7): 847-57.
41. Yaffe K, Krueger K, Sarikar S, Grady D, Barrett-Connor E, Cox DA et al. 2001 Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344(16): 1207-13.
42. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. 1995 The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99(6):636-41.
43. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT. 1994 Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992-7.
44. Paganini-Hill A, Clark LJ. 2000 Preliminary assessment of cognitive function in breast cancer patients with tamoxifen. Breast Cancer Res Treat 64(2): 165-76.
45. Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G. 2001 The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 86:5060-6.
46. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. 1983 Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 249(16): 2195-8.
47. Raz R, Stamm WE. 1993 A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infection. New Engl J Med 329(11):753-6.
47a. Hendrix S, Cochrane B, Nygaard I, Handa V, Barnabei V, Iglesia C et al. 2005 Effects of estrogen with and without progestin on urinary incontinence. JAMA 293(8): 935-948.
48. Labrie F, Belanger A, Cusan L, Gomez J-L, Candas B. 1997 Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 82:2396.
49. Judd HL, Mebane-Sims I, Legault C, Wasilaskas C, Johnson S, Merino M et al. 1996 Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 275(5):370-5.
50. The Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women's Health Initiative Randomized Control Trial. 2004 JAMA 291(14): 1701-12.
50a. Shumaker SA, et al. Conjugated Equine Estrogen and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women: Women's Health Initiative Memory Study. 2004 JAMA 291(24): 2947-58.
51. Response to Women's Health Initiative Study results by the American College of Obstetricians and Gynecologists. 8/9/2002
52. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H et al. 2002 Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 109(2): 136-44.
53. Hulley S, Grady D, Bush T, Furber C, Herrington D, Riggs B, Vittinghoff E. 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613.
54. Adams MR, Williams JK, Clarkson TB, Jayo MJ. 1991 Effects of oestrogens and progestogens on coronary artherosclerosis and osteoporosis of monkeys. Baillieres Clin Obstet Gynaecol 5(4): 915-34.
55. Clarkson TB. 1994 Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. Fertil Steril 62(6 Suppl 2): 147S-151S.
56. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B et al. 1996 Postmenopausal estrogen and progestin use and risk of cardiovascular disease. New Engl J Med 335(7): 453-61.
57. Barrett-Connor E, Grady D. 1998 Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19:55-72.
58. NAMS Board of Trustees 2004 Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause: The journal of the NAMS 11(1): 11-33.
59. ACOG Task Force on Hormone Therapy. 2004 Hormone Therapy. Obstetrics and Gynecology 104(S4): 112S
60. Loprinzi CL, Kugler JW, Sloan JA, et al. 2000 Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 356:2059-63.
61. Stearns v, Beebe KL, Iyengar M, Dube E. 2003 Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289:2827-34.
62. Ettinger B. Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. 1994 Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 83: 693-700.
63. Henriksson L, Stjernquist M, Boquist L. 1996 A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174:85–92.
64. Rioux JE, Devlin MC, Gelfand MM, Steinberg, Hepburn DS. 2000 17[beta]-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause; 7:156–61.
65. Santen RF, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, et. al. 2002 Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 9(3) 179-87.